article thumbnail

Accenture Invests in QuantHealth to Accelerate Use of AI-Powered Clinical Trial Simulations to Drive Cost-Effective Drug Development

Healthcare IT Today

Accenture announced it has made a strategic investment, through Accenture Ventures , in QuantHealth , an AI-powered clinical trial design company that simulates clinical trials in the cloud, allowing pharmaceutical and biotech companies to more quickly and cost-effectively develop treatments for patients. Petra Jantzer, Ph.D.,

article thumbnail

Patients and Industry: Starting Our New Life Together in 2023

Society for Participatory Medicine

The FDA issued a series of four patient-focused drug development (PFDD) guidance documents which outline how patient co-design needs to successfully happen. After all of this time and energy expended, it’s only right that patients would be witness to accountability of pharma/biotech to incorporate our collective voice.

BioTech 144
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

PhaseV Raises $15 Million to Push the Boundaries of ML for Clinical Trial Optimization

Healthcare IT Today

This ML-driven adaptive process can significantly accelerate the clinical drug development process and increase certainty along the way, resulting in more efficient, targeted, and ultimately more successful clinical trials. bringing new needed treatments to patients.”

article thumbnail

QuantHealth Announces $15M Series A for its AI Platform That Enhances Success of Clinical Trials

Digital Health Global

QuantHealth bridges these gaps by simulating trials at scale, to expedite, derisk, and optimize drug development. QuantHealth proudly supports several large pharma companies, numerous biotechs, as well as CROs, and other industry partners.

BioTech 88
article thumbnail

Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson’s Disease

Digital Health Global

Indivi is dedicated to unlocking the immense potential of digital biomarkers in drug development and healthcare by creating a unique symbiotic intersection between expert knowledge in Data Science, Clinical Science and Advanced Analytics (including machine learning and artificial intelligence).

article thumbnail

Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials

Digital Health Global

As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drug development. Koneksa clients gain access to a team of PhDs and MDs at SSI with expertise in drug development.

article thumbnail

Koneksa Announces Partnership with Beacon Biosignals for Clinical Trial in Sleep and Neurologic Disorders Using EEG Biomarkers

Digital Health Global

We’re on a mission to revolutionize drug development in clinical trials by harnessing the power of our digital solutions with real-time, data-driven insights. The utilization of evidence-based digital biomarkers is the key to transforming healthcare,” said Chris Benko, CEO, Koneksa. “We’re